Applying transcriptomic and proteomic knowledge to Parkinson's disease drug discovery

Abstract

It is recognised that in both genetic and sporadic cases of Parkinson's disease (PD), the basis of its etiopathology resides in the particular vulnerability of the dopaminergic neurons of the substantia nigra pars compacta (SNpc) to oxidative stress and in the failure to adequately remove abnormal proteins. These observations have been confirmed recently by microarray transcriptomic studies in human SN from PD brains and have extended understanding of the molecular pathways underlying the PD pathology. This article reviews recent gene expression profiling studies in sporadic PD postmortem SN and highlights gene candidates as putative molecular signatures for early disease diagnosis. In addition, the application of transcriptomics and proteomics in the quest for multifunctional neuroprotective–neurorescue drugs that might possess disease-modifying action is discussed.

Keywords::

• biomarkers
• gene expression profiling
• microarrays
• neuroprotective multifunctional drugs
• Parkinson's disease
• rasagiline

Notes